Drilon A.Siena S.Dziadziuszko R.Barlesi F.Krebs M.G.Shaw A.T.de Braud F.Rolfo C.Ahn M.-J.Wolf J.Seto T.Cho B.C.Patel M.R.Chiu C.-H.John T.Goto K.Karapetis C.S.Arkenau H.-T.Kim S.-W.Ohe Y.Li Y.-C.Chae Y.K.Chung C.H.Otterson G.A.Murakami H.CHIA-CHI LINTan D.S.W.Prenen H.Riehl T.Chow-Maneval E.Simmons B.Cui N.Johnson A.Eng S.Wilson T.R.Doebele R.C.2022-09-152022-09-1520201470-2045https://www.scopus.com/inward/record.uri?eid=2-s2.0-85078433419&doi=10.1016%2fS1470-2045%2819%2930690-4&partnerID=40&md5=5ccb6a6e34f61c24c358ec7171e66a61https://scholars.lib.ntu.edu.tw/handle/123456789/620241[SDGs]SDG3Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1–2 trialsjournal article10.1016/S1470-2045(19)30690-4318380152-s2.0-85078433419